Literature DB >> 1370528

Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia trachomatis major outer membrane protein.

H Su1, H D Caldwell.   

Abstract

The immunogenicity of a chimeric T/B cell peptide corresponding to antigenically characterized epitopes of the Chlamydia trachomatis major outer membrane protein (MOMP) was studied in mice to further define its potential use in the development of a subunit vaccine in preventing blinding trachoma in humans. The chimeric peptide, designated A8-VDI, corresponds to a conserved MOMP T helper (Th) cell epitope(s) (A8, residues 106-130) and serovar A VDI (residues 66-80), which contains the serovar-specific neutralizing epitope 71VAGLEK76. Mice immunized with peptide A8-VDI produced high-titered polyclonal IgG antibodies which recognized the VAGLEK-neutralizing epitope. Peptide A8-VDI primed A/J mice to produce high-titered serum-neutralizing antibodies in response to a secondary immunization with intact chlamydial elementary bodies (EBs). Peptide A8-VDI, but not peptide VDI alone, was immunogenic in six different inbred strains of mice disparate at H-2, indicating that the Th cell epitope(s) contained in the A8 portion of the chimera was recognized in the context of multiple major histocompatibility complex (MHC) haplotypes. An unexpected finding of this work was that different inbred strains of mice immunized with the chimeric peptide produced antibodies of differing fine specificities to the VDI portion of the chimera. Some mouse strains produced anti-VDI antibodies that did not recognize the VAGLEK-neutralizing epitope. The ability of mice to respond to the VAGLEK-neutralizing site was not dependent on MHC haplotype since mouse strains of the same H-2 haplotype produced anti-VDI antibodies of differing fine specificity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370528      PMCID: PMC2119084          DOI: 10.1084/jem.175.1.227

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  The major outer membrane protein nucleotide sequence of Chlamydia trachomatis, serovar E.

Authors:  E M Peterson; B A Markoff; L M de la Maza
Journal:  Nucleic Acids Res       Date:  1990-06-11       Impact factor: 16.971

2.  Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants.

Authors:  Y X Zhang; S J Stewart; H D Caldwell
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

3.  Immunity to chlamydial infections of the eye. I. The role of circulatory and secretory antibodies in resistance to reinfection with guinea pig inclusion conjunctivitis.

Authors:  E S Murray; L T Charbonnet; A B MacDonald
Journal:  J Immunol       Date:  1973-06       Impact factor: 5.422

4.  Immunity to chlamydial infections of the eye. VI. Homologous neutralization of trachoma infectivity for the owl monkey conjuctivae by eye secretions from humans with trachoma.

Authors:  R L Nichols; R E Oertley; E C Fraser; A B MacDonald; D E McComb
Journal:  J Infect Dis       Date:  1973-04       Impact factor: 5.226

5.  Experimental inclusion conjunctivitis in man: measurements of infectivity and resistance.

Authors:  E Jawetz; L Rose; L Hanna; P Thygeson
Journal:  JAMA       Date:  1965-11-08       Impact factor: 56.272

6.  Murine MHC polymorphism and T cell specificities.

Authors:  S Roy; M T Scherer; T J Briner; J A Smith; M L Gefter
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

7.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

8.  Enhancement of Chlamydia trachomatis infectious progeny by cultivation of HeLa 229 cells treated with DEAE-dextran and cycloheximide.

Authors:  S F Sabet; J Simmons; H D Caldwell
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

9.  Sequence analysis of the major outer membrane protein gene from Chlamydia trachomatis serovar L2.

Authors:  R S Stephens; G Mullenbach; R Sanchez-Pescador; N Agabian
Journal:  J Bacteriol       Date:  1986-12       Impact factor: 3.490

10.  High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis.

Authors:  R S Stephens; E A Wagar; G K Schoolnik
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  32 in total

1.  T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans.

Authors:  L Ortiz; M Angevine; S K Kim; D Watkins; R DeMars
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  Mutagenesis and functional reconstitution of chlamydial major outer membrane proteins: VS4 domains are not required for pore formation but modify channel function.

Authors:  E S Hughes; K M Shaw; R H Ashley
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

3.  Immunization with a peptide corresponding to chlamydial heat shock protein 60 increases the humoral immune response in C3H mice to a peptide representing variable domain 4 of the major outer membrane protein of Chlamydia trachomatis.

Authors:  V L Motin; L M de la Maza; E M Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

4.  T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.

Authors:  X Yang; R Brunham
Journal:  Can J Infect Dis       Date:  1998-03

5.  Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response.

Authors:  M Johansson; K Schön; M Ward; N Lycke
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

7.  Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model.

Authors:  Chunmei Cheng; Sukumar Pal; Ilham Bettahi; Kristie L Oxford; Peter A Barry; Luis M de la Maza
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

8.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

9.  Characterization of a neutralizing monoclonal antibody directed at variable domain I of the major outer membrane protein of Chlamydia trachomatis C-complex serovars.

Authors:  Z Qu; X Cheng; L M de la Maza; E M Peterson
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

10.  Characterization of the humoral response induced by a synthetic peptide of the major outer membrane protein of Chlamydia trachomatis serovar B.

Authors:  A Villeneuve; L Brossay; G Paradis; J Hébert
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.